stockrowZoetis Inc.
ZTS Healthcare Drug Manufacturers Specialty & Generic
Zoetis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.5 billion, up 2.28% from fiscal 2024.
- Revenue
- −0.24%
- EPS
- +2.48%
- Free cash flow
- +17.4%
- Total debt
- +37.5%
Quarter to June 2026, against a year earlier
Follow ZTS
Alert me
Zoetis Inc. (ZTS) Total debt
Zoetis Inc.'s total debt at the end of fiscal 2025 was $9.0B, up 37.6% from $6.6B in fiscal 2024. At the end of the quarter to 30 June 2026 it was $9.0B. Over the past ten years it has ranged from $4.5B (fiscal 2016) to $9.0B (fiscal 2025) — the current reading is the highest in ten years. Zoetis Inc. ranks 4th of 84 Drug Manufacturers Specialty & Generic companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $9.0B | 37.63% |
| FY2024 | $6.6B | 0.05% |
| FY2023 | $6.6B | (16.92%) |
| FY2022 | $7.9B | 19.16% |
| FY2021 | $6.6B | (7.86%) |
| FY2020 | $7.2B | 11.66% |
| FY2019 | $6.4B | (0.08%) |
| FY2018 | $6.5B | 30.26% |
| FY2017 | $5.0B | 10.85% |
| FY2016 | $4.5B | (8.22%) |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Jun 2026 | $9.0B | 0.03% |
| Mar 2026 | $9.0B | 0.03% |
| Dec 2025 | $9.0B | 27.91% |
| Sep 2025 | $7.1B | 7.42% |
| 42 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| TAK Takeda Pharmaceutical Co. compare | $28.8B |
| TEVA Teva Pharmaceutical Industries Ltd. compare | $16.7B |
| HLN Haleon PLC Sponsored ADR compare | $11.1B |
| ZTS Zoetis Inc. | $9.0B |
| ELAN Elanco Animal Health Incorporated compare | $3.9B |
| VTRS Viatris Inc. compare | $1.7B |
| RDY Dr. Reddy's Laboratories Ltd compare | $753.0M |
| NBIX Neurocrine Biosciences, Inc. compare | $274.0M |
| UTHR United Therapeutics Corporation compare | $200.0M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on ZTS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement